NDEV Posts Steady Q2 2026 Revenue Growth; Self-Funded Model Yields 8.8% Debt-to-Equity Ratio
MIAMI, FLORIDA - August 25, 2026 ( NEWMEDIAWIRE ) - Novus Acquisition & Development Corp. (OTC: NDEV), doing business as Novus Cannabis MedPlan, today announced the release of its Q2 2026 Interim Report. The disclosure confirms consistent revenue growth and a defensive capital structure designed to insulate equity from the systemic debt crisis currently affecting plant-touching operators. Financial & Operational Highlights Revenue Growth: In Q2 2026, gross revenue experienced a year-over-year increase of 7.7%, reaching a total of $214,398 for the six-month period when compared to the Q2 2025 report. Solvency & Capital Efficiency: Novus follows a disciplined, self-funded business model, maintaining a conservative 8.8% debt-to-equity ratio. All existing liabilities are held internally by the CEO, and they do not have call provisions or equity-conversion features. No Convertible Debt: NDEV maintains zero outstanding convertible notes or convertible debentures. The sole operating capital provided by the CEO carries no conversion features, ensuring shareholders remain completely insulated from the equity dilution typically triggered by debt-to-equity conversions. Vendor Share Leak-Out P
Forfait Gratuit · Plus 29 $ CA ou Pro 99 $ CA/mois


